How effective is Mobocertinib?

Mobocertinib (Mobocertinib) is a new oral drug used to treat EGFR gene mutation-positive advanced or metastatic non-small cell lung cancer (NSCLC). The efficacy and clinical application of mobosertinib will be introduced in detail below based on clinical trial data.

Clinical trial on the efficacy of mobosetinib

Clinical trials of mobosetinib mainly include key clinical trial stages, including I/IIphase and IIIphase trials to evaluate the safety and efficacy of the drug.

1. Early stage research (I/II phase trial)

Mobosetinib was initially evaluated in Phase I/II trials, which were primarily designed to determine tolerability and appropriate dosing of the drug. Results from these early trials suggest that mobosetinib has potential therapeutic benefit in patients with EGFR T790M mutation-positive NSCLC.

2. PivotalIIIPhase Trial

PivotalPhase III clinical trials (such asADRIATIC, EXCLAIM and MELKIOR), trials designed to compare moboxetinib with other treatments such as standard EGFR Performance of TKItherapy or chemotherapy) in EGFR T790M mutation-positive NSCLC patients.

- ADRIATICTrial

ADRIATICThe trial is an importantIIIA phase 1 clinical trial is designed to compare the performance of moboxetinib with standard EGFR TKI treatment in terms of progression-free survival (PFS) in EGFR T790Mpositive NSCLC patients. Results from the trial showed that moboxetinib significantly prolonged PFS, keeping patients' disease stable for longer. This suggests that mobosertinib has better efficacy in this patient population.

- EXCLAIMExperiment

The EXCLAIMtrial further evaluated the efficacy of mobosetinib compared with chemotherapy in terms of disease control rates and survival in patients with EGFR T790MpositiveNSCLC. Trial results showed that mobosetinib showed advantages in controlling the disease and improved patient survival.

- MELKIORTest

The MELKIORtrial is another pivotal Phase III clinical trial comparing mobosetinib with standardEGFR TKItreatment in EGFR Survival and safety in patients with T790MpositiveNSCLC. Trial results showed that mobosetinib was significantly successful in prolonging patient survival and had an acceptable safety profile.

Clinical application of moboxetinib

Based on the above clinical trial data, mobosetinib has shown excellent efficacy and safety in EGFR T790MpositiveNSCLC patients. It provides an effective treatment option, especially for patients who have developed resistance to other EGFR TKI drugs. The drug's efficacy and safety profile make it an important treatment option for patients with advanced NSCLC.

In summary, the positive results of multiple clinical trials of mobosetinib have demonstrated its significant efficacy in EGFR T790MpositiveNSCLC patients. The introduction of this drug provides new treatment hope for patients with advanced NSCLC and is expected to improve their survival and quality of life. However, it should be noted that specific treatment decisions should be made jointly by the patient and physician based on the patient's specific situation and medical history. As time goes by, more studies and data are likely to further confirm the efficacy of moboxetinib.

Mobotinib is currently on the market in China, but it is not included in medical insurance. Patients need to pay for it in full, so the price is very high. Please consult the local hospital pharmacy for specific prices. Other versions include the Hong Kong version of the original drug Mobotinib, which costs around 7,000 to 8,000 yuan. The generic drug of Mobotinib is mainly a Laotian generic drug. The price is about three to four thousand yuan, which is nearly half cheaper than the original drug. The ingredients of the original drug and the generic drug are the same.